Edition:
United States

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

121.21USD
20 Nov 2018
Change (% chg)

-- (--)
Prev Close
$121.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
130,668
52-wk High
$179.65
52-wk Low
$105.22

Chart for

About

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers... (more)

Overall

Beta: 2.68
Market Cap(Mil.): $2,789.42
Shares Outstanding(Mil.): 2.11
Dividend: --
Yield (%): --

Financials

  GWPH.OQ Industry Sector
P/E (TTM): -- 83.62 33.60
EPS (TTM): -5.56 -- --
ROI: -38.35 -0.65 15.05
ROE: -41.13 0.07 16.62

GW Pharma cannabis drug set to hit market following DEA nod

U.S.-listed shares of GW Pharmaceuticals rose 8 percent on Thursday as its marijuana-based treatment Epidiolex cleared the last hurdle after the Drug Enforcement Administration labeled the drug as having a low abuse potential.

Sep 27 2018

UPDATE 2-Zogenix's seizure drug clears late-stage trial, shares soar

July 12 Zogenix Inc said on Thursday its drug to treat a rare form of childhood epilepsy reduced convulsive seizures in a second late-stage trial, sending the drug developer's shares up as much as 26 percent.

Jul 12 2018

U.S. approves first marijuana plant-derived drug for epilepsy

The U.S. health regulator approved GW Pharmaceuticals Plc's epilepsy treatment on Monday, making it the first cannabis-based drug to win approval in the country and opening floodgates for more research into the medicinal properties of cannabis.

Jun 26 2018

RPT-UPDATE 4-U.S. approves first marijuana plant-derived drug for epilepsy

* FDA approves GW's drug to treat two severe forms of epilepsy

Jun 25 2018

CORRECTED-(OFFICIAL)-UPDATE 3-U.S. approves first marijuana plant-derived drug for epilepsy

* FDA approves GW's drug to treat two severe forms of epilepsy

Jun 25 2018

GW Pharma wins U.S. approval for marijuana-derived epilepsy drug

June 25 An epilepsy treatment from GW Pharmaceuticals Plc on Monday secured an approval from the U.S. Food and Drug Administration, becoming the first cannabis-based drug to be approved in the country.

Jun 25 2018

Earnings vs. Estimates